Kristi Mizelle, MD
Rheumatology · Newport News, VANPI 1457490955
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $775,697 of the $1,100,788 with a category attached, or 70.5%. 41 manufacturers reported payments, led by AbbVie at 24.4% of the total. Among rheumatology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,832 payments — averaging $600.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$268K
- Lilly USA, LLC$229K
- Amgen$223K
- GSK$125K
- Johnson & Johnson$104K
- Pfizer$39K
- plus $113K from 35 others
Across 42 payments — averaging $3251.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$64K
- Novartis$34K
- Eli Lilly$30K
- Pfizer$6K
- Janssen Research & Development, LLC$3K
What the payments were for
- Consulting fees$140,37013%
- Speaking & faculty fees$775,69770%
- Travel & lodging$148,31413%
- Food & beverage$36,1413%
- Education$2650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,100,788 in reported general payments places this provider in the 95th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $443,375 |
| Enbrel SureclickEtanercept | 39 | $346,469 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $281,400 |
| OtezlaApremilast | 30 | $89,892 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,612 |
| RinvoqUpadacitinib | 12 | $75,804 |
| KevzaraSarilumab | 15 | $74,953 |
| Hydroxychloroquine Sulfate | 468 | $18,713 |
| Leflunomide | 160 | $12,768 |
| MethotrexateMethotrexate Sodium | 411 | $12,384 |
| Colchicine | 45 | $4,150 |
| Mycophenolate Mofetil | 31 | $3,897 |
| Leucovorin Calcium | 40 | $3,065 |
| Pilocarpine Hcl | 14 | $1,713 |
| Azathioprine | 25 | $1,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $38,682 | $281,40026 claims |
| AmgenOtezla | $223,293 | $89,89230 claims |
| AbbVieRinvoq | $268,225 | $75,80412 claims |
| SanofiKevzara | $24,408 | $74,95315 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $83 | $8213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Newport News
- Peter LipskyCharlottesville$1.3M
- Phillip KempfArlington$321K
- Sharukh ShroffDanville$216K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Chase CorreiaHampton$70K
- Alexia GospodinoffReston$27K
- Donald KimpelCharlottesville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.